SPOTLIGHT -
AMCP Nexus 2021: Cate Lockhart of Biologics and Biosimilars Collective Intelligence Consortium Discusses Biosimilars Such as Semglee and the Current Standing of Biosimilars, PBMs
Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.
Read More
AMCP Nexus 2021: Jen Norton, VP & Head of U.S. Value & Access at Amgen Talks Biosimilar Trends and What to Expect in the Next Year
Jen Norton spoke at AMCP Nexus about biosimilar trends of 2021 and what to expect in the next 12 months
FDA Issues Contingency Guidance for Clinical Trials Affected by COVID-19
CROs are also adapting to pandemic.